Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30893
Title: Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.
Austin Authors: Denton, Christopher P;Goh, Nicole S L ;Humphries, Stephen M;Maher, Toby M;Spiera, Robert;Devaraj, Anand;Ho, Lawrence;Stock, Christian;Erhardt, Elvira;Alves, Margarida;Wells, Athol U
Affiliation: Center for Interstitial Lung Diseases, University of Washington, Seattle, Washington, USA
Department of Radiology, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UK
National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK
Department of Radiology, National Jewish Health, Denver, Colorado, USA
National Heart and Lung Institute, Imperial College London, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA
Respiratory and Sleep Medicine
Centre for Rheumatology and Connective Tissue Diseases, University College London Division of Medicine, London, UK
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein.
mainanalytics GmbH, Sulzbach, Germany.
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Institute for Breathing and Sleep
Issue Date: May-2023
Date: 2022
Publication information: Rheumatology (Oxford, England) 2023-05-02; 62(5)
Abstract: To assess associations between the extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial. We used generalised additive models, which involve few assumptions and allow for interaction between non-linear effects, to assess associations between the extent of fibrotic ILD on high-resolution computed tomography (HRCT), and the interplay of extent of fibrotic ILD on HRCT and FVC % predicted, at baseline and FVC decline over 52 weeks. In the placebo group (n = 288), there was weak evidence of a modest association between a greater extent of fibrotic ILD at baseline and a greater decline in FVC % predicted at week 52 (r: -0.09 [95% CI -0.2, 0.03]). Higher values of both the extent of fibrotic ILD and FVC % predicted at baseline tended to be associated with greater decline in FVC % predicted at week 52. In the nintedanib group (n = 288), there was no evidence of an association between the extent of fibrotic ILD at baseline and decline in FVC % predicted at week 52 (r: 0.01 [95% CI: -0.11, 0.12]) or between the interplay of extent of fibrotic ILD and FVC % predicted at baseline and decline in FVC % predicted at week 52. Data from the SENSCIS trial suggest that patients with SSc-ILD are at risk of ILD progression and benefit from nintedanib largely irrespective of their extent of fibrotic ILD at baseline. ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30893
DOI: 10.1093/rheumatology/keac535
ORCID: 
Journal: Rheumatology (Oxford, England)
PubMed URL: 36111858
Type: Journal Article
Subjects: autoimmune diseases
pulmonary fibrosis
vital capacity
Appears in Collections:Journal articles

Show full item record

Page view(s)

54
checked on Oct 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.